<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="es"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurologia</journal-id><journal-id journal-id-type="iso-abbrev">Neurologia</journal-id><journal-title-group><journal-title>Neurologia (Barcelona, Spain)</journal-title></journal-title-group><issn pub-type="ppub">0213-4853</issn><issn pub-type="epub">1578-1968</issn><publisher><publisher-name>Sociedad Espa&#x000f1;ola de Neurolog&#x000ed;a. Published by Elsevier Espa&#x000f1;a, S.L.U.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7380252</article-id><article-id pub-id-type="publisher-id">S0213-4853(20)30230-9</article-id><article-id pub-id-type="doi">10.1016/j.nrl.2020.07.004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Relaci&#x000f3;n entre COVID-19 y s&#x000ed;ndrome de Guillain-Barr&#x000e9; en adultos. Revisi&#x000f3;n sistem&#x000e1;tica</article-title><trans-title-group xml:lang="en"><trans-title>Relation between COVID-19 and Guillain-Barr&#x000e9; syndrome in adults. Systematic review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Trujillo Gittermann</surname><given-names>L.M.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Valenzuela Feris</surname><given-names>S.N.</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>von Oetinger Giacoman</surname><given-names>A.</given-names></name><xref rid="aff0020" ref-type="aff">d</xref><xref rid="aff0025" ref-type="aff">e</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff0005"><label>a</label>Escuela de Kinesiolog&#x000ed;a, Facultad de Ciencias de la Salud, Universidad de las Am&#x000e9;ricas, Santiago, Chile</aff><aff id="aff0010"><label>b</label>Escuela de Kinesiolog&#x000ed;a, Facultad de Salud y Odontolog&#x000ed;a, Universidad Diego Portales, Santiago, Chile</aff><aff id="aff0015"><label>c</label>Centro M&#x000e9;dico Dental RedSalud, Maip&#x000fa;. Unidad de Kinesiolog&#x000ed;a Ambulatoria, Santiago, Chile</aff><aff id="aff0020"><label>d</label>Escuela de Kinesiolog&#x000ed;a, Facultad de Ciencias de la Salud, Universidad San Sebasti&#x000e1;n, Santiago, Chile</aff><aff id="aff0025"><label>e</label>Direcci&#x000f3;n de Postgrado, Facultad de Ciencias, Universidad Mayor, Santiago, Chile</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Autora para correspondencia.</corresp></author-notes><pub-date pub-type="pmc-release"><day>24</day><month>7</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>24</day><month>7</month><year>2020</year></pub-date><history><date date-type="received"><day>28</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>9</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Sociedad Espa&#x000f1;ola de Neurolog&#x000ed;a. Published by Elsevier Espa&#x000f1;a, S.L.U.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Sociedad Espa&#x000f1;ola de Neurolog&#x000ed;a</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><sec><title>Introducci&#x000f3;n</title><p>Se han reportado distintos casos de pacientes con cuadro de s&#x000ed;ndrome de Guillain-Barr&#x000e9; asociado a COVID-19, pero falta mucha informaci&#x000f3;n a&#x000fa;n sobre esta asociaci&#x000f3;n y sus implicancias, el objetivo de esta revisi&#x000f3;n es analizar la evidencia disponible en esta tem&#x000e1;tica en la poblaci&#x000f3;n adulta.</p></sec><sec><title>Material y M&#x000e9;todos</title><p>Se realiz&#x000f3; una revisi&#x000f3;n sistem&#x000e1;tica de estudios publicados en buscadores cient&#x000ed;ficos: PubMed, Cochrane, Science Direct, Medline, OMS COVID-19.</p></sec><sec><title>Resultados</title><p>Se identificaron 45 estudios, los cuales se analizaron y completaron utilizando la plataforma Covidence, incluyendo para el an&#x000e1;lisis final 24 art&#x000ed;culos y sumando un total de 30 pacientes.</p></sec><sec><title>Conclusiones</title><p>Se demuestra una asociaci&#x000f3;n fuerte entre ambas patolog&#x000ed;as, adem&#x000e1;s, los estudios analizados recalcan diferencias en la presentaci&#x000f3;n de la enfermedad con mayor gravedad en los cuadros de s&#x000ed;ndrome de Guillain-Barr&#x000e9; asociados a COVID-19.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Numerous cases have been reported of patients with symptoms of Guillain-Barr&#x000e9; syndrome associated with COVID-19, but much information is still lacking on this association and its implications. The objective of this review is to analyse the available evidence on this topic in the adult population.</p></sec><sec><title>Material and methods</title><p>A systematic review was conducted of studies published on scientific databases: PubMed, Cochrane, Science Direct, Medline, and WHO COVID-19 database.</p></sec><sec><title>Results</title><p>We identified 45 studies, which were analysed and completed using the Covidence platform; the final analysis included 24 articles, with a total of 30 patients.</p></sec><sec><title>Conclusions</title><p>We found a strong association between both conditions; furthermore, the studies analysed highlight differences in the presentation of the disease, with greater severity of symptoms in Guillain-Barre syndrome associated with COVID-19.</p></sec></trans-abstract><kwd-group id="kwd0005"><title>Palabras clave</title><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>Guillain-Barr&#x000e9;</kwd><kwd>Neuropat&#x000ed;as</kwd><kwd>Enfermedades desmielinizantes</kwd></kwd-group><kwd-group xml:lang="en" id="kwd0010"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>Guillain-Barr&#x000e9; syndrome</kwd><kwd>Neuropathies</kwd><kwd>Demyelinating diseases</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>Introducci&#x000f3;n</title><p id="par0005">La pandemia por la que estamos cursando no tiene precedentes, el virus SARS-CoV-2 que produce la enfermedad COVID-19 a&#x000fa;n no termina de mostrar sus alcances, es as&#x000ed; como cada d&#x000ed;a se descubren nuevos hallazgos respecto a formas de contagio, s&#x000ed;ntomas, evoluci&#x000f3;n, nuevas cepas, inmunidad y asociaci&#x000f3;n con otras patolog&#x000ed;as<xref rid="bib0190" ref-type="bibr"><sup>1</sup></xref>. Respecto a esto &#x000fa;ltimo, se ha visto que este virus no solo genera implicancias y deterioros sobre el sistema respiratorio, sino que tambi&#x000e9;n sobre otros sistemas como el vascular, renal y tambi&#x000e9;n el sistema nervioso central<xref rid="bib0195" ref-type="bibr"><sup>2</sup></xref>.</p><p id="par0010">Se han reportado varios casos en distintos centros de salud, de ingreso de pacientes que presentan s&#x000ed;ndrome de Guillain-Barr&#x000e9; (SGB) y son COVID-19 positivo activos o cursaron con la enfermedad, por lo que se ha planteado la asociaci&#x000f3;n entre ambas patolog&#x000ed;as. Algunos autores manifiestan que la presentaci&#x000f3;n de SGB que se asocia a COVID-19 genera s&#x000ed;ntomas de aparici&#x000f3;n m&#x000e1;s aguda, por lo que pareciera ser una forma del SGB pre-pandemia<xref rid="bib0200" ref-type="bibr"><sup>3</sup></xref>.</p><p id="par0015">Se ha descrito en otros tipos de coronavirus (CoV), que &#x000e9;stos suelen invadir el sistema nervioso central, por lo que se consideran virus potencialmente neuroinvasivos, generando distintas manifestaciones y secuelas tras su paso, afectando a neuronas y c&#x000e9;lulas gliales<xref rid="bib0205" ref-type="bibr"><sup>4</sup></xref>. Estas manifestaciones del sistema nervioso central se pueden clasificar en tres tipos: encefalitis virales, descritas como lesiones de tipo inflamatorias en el par&#x000e9;nquima cerebral; encefalopat&#x000ed;a infecciosa aguda/t&#x000f3;xica, descrita como s&#x000ed;ndrome de disfunci&#x000f3;n cerebral reversible causado por cuadros t&#x000f3;xicos sist&#x000e9;micos, trastornos metab&#x000f3;licos e hipoxia durante un per&#x000ed;odo de infecci&#x000f3;n aguda; y por &#x000fa;ltimo, la enfermedad cerebrovascular aguda (ataque cerebrovascular), que en los &#x000fa;ltimos meses ha sido ampliamente atribuida al SARS-CoV-2, debido a que este virus causa una cascada de citoquinas proinflamatorias, encontr&#x000e1;ndose tambi&#x000e9;n niveles elevados de d&#x000ed;mero-D y bajos niveles de plaquetas, pudiendo presentarse un ataque cerebrovascular<xref rid="bib0205" ref-type="bibr"><sup>4</sup></xref>.</p><p id="par0020">El SGB es una enfermedad considerada grave, que ocurre cuando el sistema inmune del afectado ataca al propio cuerpo, espec&#x000ed;ficamente a c&#x000e9;lulas del sistema nervioso perif&#x000e9;rico. La causa no est&#x000e1; clara, pero se ha visto que este trastorno inmunitario muchas veces se asocia a otras patolog&#x000ed;as ya sean virales o bacterianas, como influenza, VIH, virus herpes y ahora se busca asociaci&#x000f3;n con COVID-19<xref rid="bib0210" ref-type="bibr"><sup>5</sup></xref>. A pesar de que el SGB se puede presentar a cualquier edad, tiene mayor incidencia entre los 30-50 a&#x000f1;os. Se denomina enfermedad desmielinizante porque el da&#x000f1;o principal se ve en la mielina de los nervios perif&#x000e9;ricos, lo que genera paresia, debilidad muscular, hasta par&#x000e1;lisis ascendente de presentaci&#x000f3;n bilateral. Si los da&#x000f1;os neurales alcanzan a los nervios diafragm&#x000e1;ticos, el paciente presenta desde dificultad respiratoria leve hasta necesidad de asistencia ventilatoria invasiva. Lamentablemente el SGB no tiene cura, solo manejo sintom&#x000e1;tico y soporte ventilatorio en caso de requerirse<xref rid="bib0210" ref-type="bibr"><sup>5</sup></xref>.</p><p id="par0025">En diversos estudios patol&#x000f3;gicos, entre ellos el de Hamming et al., se evidenci&#x000f3; que la ACE2 (enzima convertidora de angiotensina 2) act&#x000fa;a como receptor funcional de SARS-CoV en los tejidos humanos<xref rid="bib0215" ref-type="bibr"><sup>6</sup></xref>. Debido a la similitud secuencial de las prote&#x000ed;nas S (en ingl&#x000e9;s, <italic>spike proteins</italic>) del SARS-CoV y SARS-CoV-2, se realiz&#x000f3; la predicci&#x000f3;n de que SARS-CoV-2 tambi&#x000e9;n utiliza ACE2 como receptor funcional, informaci&#x000f3;n que fue confirmada por otros estudios durante los primeros meses del 2020<xref rid="bib0220" ref-type="bibr">7</xref>, <xref rid="bib0225" ref-type="bibr">8</xref>.</p><p id="par0030">Tambi&#x000e9;n se han planteado como posibles mecanismos por los cuales el SARS-CoV-2 puede causar da&#x000f1;os neurol&#x000f3;gicos, el anclaje del virus a la ACE2 en la barrera hematoencef&#x000e1;lica, facilitando su ingreso al sistema nervioso central; as&#x000ed; como tambi&#x000e9;n se ha propuesto que existen v&#x000ed;as de diseminaci&#x000f3;n neural retr&#x000f3;grada, transcribal y hemat&#x000f3;gena<xref rid="bib0230" ref-type="bibr">9</xref>, <xref rid="bib0235" ref-type="bibr">10</xref>.</p><p id="par0035">El objetivo de esta revisi&#x000f3;n es analizar la evidencia disponible sobre las asociaciones descritas entre el COVID-19 y el SGB en la poblaci&#x000f3;n adulta, a fin de dar a conocer las manifestaciones cl&#x000ed;nicas y evoluci&#x000f3;n en los casos reportados, para as&#x000ed; aportar informaci&#x000f3;n relevante que permita un manejo preventivo frente a la patolog&#x000ed;a.</p></sec><sec id="sec0010"><title>Material y m&#x000e9;todo</title><p id="par0040">Nuestro art&#x000ed;culo es una revisi&#x000f3;n sistem&#x000e1;tica que incluye los art&#x000ed;culos relacionados con los siguientes t&#x000e9;rminos MeSH: COVID-19, SARS-CoV-2, Guillain-Barr&#x000e9;, neuropat&#x000ed;as y enfermedad desmielinizante. Considerando art&#x000ed;culos de revisi&#x000f3;n sistem&#x000e1;tica (SR), art&#x000ed;culos controlados randomizados (RTC), ensayos cl&#x000ed;nicos controlados (CCT) y estudios observacionales, serie de casos (SC) y reporte de caso (RC). Los art&#x000ed;culos incluidos en la revisi&#x000f3;n fueron publicados entre Diciembre 2019 y Junio 2020, considerando los estudios realizados en poblaci&#x000f3;n adulta. Los buscadores cient&#x000ed;ficos utilizados fueron: PubMed, Cochrane, Science Direct, Medline, buscador OMS COVID-19. Los art&#x000ed;culos de revisi&#x000f3;n bibliogr&#x000e1;fica y opini&#x000f3;n de expertos no fueron incluidos.</p><p id="par0045">El protocolo para llevar a cabo la presente revisi&#x000f3;n sistem&#x000e1;tica fue guiado por la declaraci&#x000f3;n PRISMA <italic>(Preferred Reporting Items for Systematic Review and Meta-Analysis)</italic> y ejecutado a trav&#x000e9;s de la plataforma Covidence&#x000ae;. La evaluaci&#x000f3;n de sesgo de los estudios incluidos fue realizada por dos revisores de forma independiente. Todos los conflictos fueron resueltos entre los investigadores por consenso. Se utiliz&#x000f3; la herramienta de evaluaci&#x000f3;n de calidad publicada por el NIH (National Heart, Lung and Blood Institute) en su sitio web <ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools" id="intr0005">https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</ext-link>.</p></sec><sec id="sec0015"><title>Resultados</title><p id="par0050">De los 45 art&#x000ed;culos identificados en la b&#x000fa;squeda bibliogr&#x000e1;fica, siete se eliminaron por estar duplicados, 15 quedaron excluidos en la fase de Revisi&#x000f3;n de T&#x000ed;tulos y Abstracts, de los 23 art&#x000ed;culos restantes, uno qued&#x000f3; excluido en la fase de Revisi&#x000f3;n Full Text por dise&#x000f1;o de estudio. &#x000da;nicamente los 24 art&#x000ed;culos restantes se utilizaron para la obtenci&#x000f3;n de datos, an&#x000e1;lisis de resultados y fueron sometidos a evaluaci&#x000f3;n de calidad (<xref rid="fig0005" ref-type="fig">fig. 1</xref>
). El n&#x000fa;mero total de pacientes incluidos fue de 30, en cinco de estos pacientes no fue reportado el sexo ni la edad (16,6%), de los 25 pacientes restantes encontramos 14 hombres (46,6%) y 11 mujeres (36,6%).<fig id="fig0005"><label>Figura 1</label><caption><p>Diagrama de flujo para la selecci&#x000f3;n de art&#x000ed;culos.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="par0055">El gran porcentaje de los estudios incluidos report&#x000f3; el test PCR como medio de evaluaci&#x000f3;n para COVID-19, la cual result&#x000f3; ser positiva en la mayor&#x000ed;a de los pacientes; solo se aprecian tres estudios con presencia de PCR negativa, dentro de los cuales encontramos a Molina et al., en donde los autores clasifican el resultado del examen como falso negativo, por encontrarse en el entorno familia de la paciente casos confirmados de COVID-19. En el estudio de Reyes-Bueno et al., en donde la PCR fue negativa, pero el test de IgG resulta positivo, y por &#x000fa;ltimo, el estudio de Toscano et al., donde de los cinco pacientes reportados, solo uno result&#x000f3; con PCR negativa<xref rid="bib0240" ref-type="bibr">11</xref>, <xref rid="bib0245" ref-type="bibr">12</xref>, <xref rid="bib0250" ref-type="bibr">13</xref>. Destaca el estudio de Kilinc et al., donde los autores no reportan toma de PCR, sino solamente examen de IgM e IgG, siendo ambos positivos<xref rid="bib0255" ref-type="bibr"><sup>14</sup></xref>.</p><p id="par0060">Dentro de lo reportado respecto a presencia de SARS-CoV-2 en l&#x000ed;quido cefalorraqu&#x000ed;deo (LCR), todos los pacientes mostraron ausencia del virus en este medio (resultados negativos).</p><p id="par0065">Si analizamos las manifestaciones cl&#x000ed;nicas reportadas en los estudios analizados, dentro de las m&#x000e1;s frecuentes encontramos la debilidad muscular de extremidades inferiores, arreflexia, afectaci&#x000f3;n de los nervios craneales (par&#x000e1;lisis facial, diplej&#x000ed;a facial, disfagia, entre otros), paraparesias y cuadriparesias, seguidas de signos levemente menos frecuentes como tos, fiebre, diarrea, dificultad respiratoria, anosmia, ageusia, entre otros.</p><p id="par0070">Respecto al cuadro febril como sintomatolog&#x000ed;a, se vio presente en la mayor&#x000ed;a de los casos reportados; sin embargo, hay que considerar que varios de los pacientes estaban con COVID-19 activo en el momento de ser ingresados y, en el caso de los pacientes que no presentaron fiebre, fue debido a que el SGB se present&#x000f3; 10, 14 y hasta 21 d&#x000ed;as posteriores al diagn&#x000f3;stico de COVID-19.</p><p id="par0075">Referente al tratamiento, en la mayor&#x000ed;a de los pacientes (90%) se utilizaron las inmunoglobulinas y en algunos estudios se a&#x000f1;adi&#x000f3; la terapia retroviral (27%) e hidroxicloroquina (40%), con la excepci&#x000f3;n de los estudios de Juliao et al., donde no se utilizan inmunoglobulinas, sino que solamente hidroxicloroquina, prednisona y terapia retroviral<xref rid="bib0260" ref-type="bibr"><sup>15</sup></xref>, el de Marta-Enguita et al., donde se prescribe morfina, AINE, pirazolonas, amoxicilina, azitromicina y &#x000e1;cido clavul&#x000e1;nico, por &#x000fa;ltimo encontramos el estudio de Oguz-Akarsu et al., quien utiliza transfusiones de plasma sangu&#x000ed;neo, hidroxicloroquina y azitromicina<xref rid="bib0265" ref-type="bibr">16</xref>, <xref rid="bib0270" ref-type="bibr">17</xref>.</p><p id="par0080">Dentro de los pacientes incluidos en la presente revision, se reportaron dos muertes, una en el estudio de Alberti et al. y otra en el estudio de Marta-Enguita et al.<xref rid="bib0265" ref-type="bibr">16</xref>, <xref rid="bib0275" ref-type="bibr">18</xref>. Sin embargo, dos autores no reportaron la evoluci&#x000f3;n de los pacientes, Camdessanche et al. y Ottaviani D. et al.<xref rid="bib0280" ref-type="bibr">19</xref>, <xref rid="bib0285" ref-type="bibr">20</xref>, y la evoluci&#x000f3;n descrita como favorable alcanz&#x000f3; al 80% de los casos reportados.</p><p id="par0085">Las principales caracter&#x000ed;sticas de los pacientes se describen en la <xref rid="tbl0005" ref-type="table">tabla 1</xref>
.<table-wrap position="float" id="tbl0005"><label>Tabla 1</label><caption><p>Caracter&#x000ed;sticas de los estudios y pacientes incluidos</p></caption><alt-text id="at1">Tabla 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Tipo de estudio</th><th align="left">n</th><th align="left">Sexo Edad</th><th align="left">S&#x000ed;ntomas y signos cl&#x000ed;nicos</th><th align="left">Sars-CoV-2</th><th align="left">Tratamiento</th><th align="left">Evoluci&#x000f3;n</th></tr></thead><tbody><tr><td align="left">Alberti P. Italia, 2020<xref rid="bib0275" ref-type="bibr"><sup>18</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino<break/>71 a&#x000f1;os</td><td align="left">-Fiebre, neumon&#x000ed;a<break/>-Parestesia, hiperestesia y debilidad sim&#x000e9;trica de extremidades, arreflexia</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo<break/>(-) LCR<break/></td><td align="left">-Manejo respiratorio<break/>-Ig<break/>-Terapia antiviral</td><td align="left">&#x0253c;</td></tr><tr><td align="left">Arnaud S.<break/>Francia, 2020<xref rid="bib0305" ref-type="bibr"><sup>23</sup></xref></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino<break/>64 a&#x000f1;os</td><td align="left">-Neumon&#x000ed;a<break/>-Parestesia, arreflexia e hipoparesia de extremidades<break/>-Disociaci&#x000f3;n albumino citol&#x000f3;gica en LCR<break/>-Patr&#x000f3;n desmielinizantes</td><td align="left">(+) PCR, hisopo<break/>nasofar&#x000ed;ngeo<break/>(-) LCR</td><td align="left">-Hidroxicloroquina, ceftriaxona y azitromicina<break/>- Ig<break/></td><td align="left">Favorable</td></tr><tr><td align="left">Assini A.<break/>Italia, 2020<xref rid="bib0310" ref-type="bibr"><sup>24</sup></xref><break/></td><td align="left">SC</td><td align="left">2</td><td align="left">CASO 1:<break/>Masculino<break/>55 a&#x000f1;os<break/><break/>CASO 2:<break/>Masculino<break/>60 a&#x000f1;os<break/></td><td align="left">-Anosmia, ageusia, debilidad mas&#x000e9;tero bilateral, par&#x000e1;lisis nervio hipogloso<break/>-Linfositopenia<break/>-Hiporefexia de extremidades<break/>-Patr&#x000f3;n desmielinizante de extremidades<break/><break/>-Fiebre, tos, neumon&#x000ed;a<break/>-Linfocitopenia<break/>-Debilidad extremidades con ca&#x000ed;da del pie<break/>-Gastropleja, arreflexia<break/>-Polineuropat&#x000ed;a</td><td align="left">(+) PCR orofar&#x000ed;ngea<break/>(-) LCR<break/><break/>(+) PCR, hisopo nasofar&#x000ed;ngeo<break/>(-) LCR<break/></td><td align="left">-Manejo respiratorio<break/>-Terapia antiviral<break/>-Ig<break/><break/><break/>-Hidroxicloroquina, ceftriaxona<break/>-Terapia antiviral<break/>-Ig</td><td align="left">Favorable<break/><break/>Favorable<break/></td></tr><tr><td align="left">Bigaut K.<break/>Francia, 2020<xref rid="bib0315" ref-type="bibr"><sup>25</sup></xref><break/></td><td align="left">SC</td><td align="left">2</td><td align="left">CASO 1:<break/>Masculino<break/>43 a&#x000f1;os<break/><break/>CASO 2:<break/>Femenino<break/>70 a&#x000f1;os<break/></td><td align="left">-Astenia, mialgia, anosmia, ageusia<break/>-Hipoestesia, debilidad EEII, ataxia, par&#x000e1;lisis facial, arreflexia EEII y b&#x000ed;ceps iz.<break/>- Afectaci&#x000f3;n nervios craneales<break/>- Patr&#x000f3;n desmielinizante<break/><break/>-Diarrea, insuficiencia respiratoria<break/>-Tetraparesia fl&#x000e1;cida, arreflexia, parestesia de las extremidades, astenia, mialgia, anosmia, ageusia<break/>-Par&#x000e1;lisis facial, afectaci&#x000f3;n nervios craneales<break/>-Patr&#x000f3;n desmielinizante</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo<break/><break/>(-) LCR<break/><break/>(+) PCR, hisopo<break/>nasofar&#x000ed;ngeo<break/><break/>(-) LCR<break/></td><td align="left">-Ig<break/><break/>-Ig</td><td align="left">Favorable<break/><break/>Favorable<break/></td></tr><tr><td align="left">El Otmani<break/>Marruecos, 2020<xref rid="bib0320" ref-type="bibr"><sup>26</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino<break/>70 a&#x000f1;os</td><td align="left">-Parestesia y debilidad de extremidades<break/>-Tetraplejia, hipoton&#x000ed;a, arreflexia</td><td align="left">(+) PCR, hisopo orofar&#x000ed;ngeo<break/>(-) LCR</td><td align="left">-Hidroxicloroquina, azitromicina<break/>-Ig</td><td align="left">Lenta pero favorable</td></tr><tr><td align="left">Molina E.<break/>Espa&#x000f1;a, 2020<xref rid="bib0240" ref-type="bibr"><sup>11</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino<break/>55 a&#x000f1;os</td><td align="left">-Fiebre, tos<break/>-Parestesia manos y pies<break/>-Debilidad EEII progresiva<break/>- Disfagia, tetraparesia arrefl&#x000e9;xica<break/>- Signos de afectaci&#x000f3;n nervios craneales.<break/></td><td align="left">(-) PCR, hisopo<break/>nasofar&#x000ed;ngeo (se cataloga como falso -)<break/>(-) PCR</td><td align="left">-Hidroxicloroquina, ceftriaxona y azitromicina<break/>- Ig<break/></td><td align="left">Favorable</td></tr><tr><td align="left">Juliao D.S.<break/>Espa&#x000f1;a, 2020<xref rid="bib0260" ref-type="bibr"><sup>15</sup></xref></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino<break/>61 a&#x000f1;os</td><td align="left">-Tos, fiebre, neumon&#x000ed;a<break/>-Par&#x000e1;lisis facial</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo<break/>(-) LCR</td><td align="left">-Hidroxicloroquina, lopinavir<break/>-Prednisona</td><td align="left">Favorable</td></tr><tr><td align="left">Camdessanche J.P. Francia, 2020<xref rid="bib0280" ref-type="bibr"><sup>19</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino<break/>64 a&#x000f1;os</td><td align="left">-Tos, fiebre, neumon&#x000ed;a<break/>-Parestesia, tetraparesia fl&#x000e1;cida severa.<break/>-Arreflexia, disfagia<break/>-Patr&#x000f3;n desmielinizante</td><td align="left">(+) PCR, hisopo orofar&#x000ed;ngeo</td><td align="left">-Ig</td><td align="left">NR</td></tr><tr><td align="left">Kilinc D. Pa&#x000ed;ses Bajos, 2020<xref rid="bib0255" ref-type="bibr"><sup>14</sup></xref></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino<break/>50 a&#x000f1;os</td><td align="left">-Diplejia facial, parestesia de extremidades, marcha at&#x000e1;xica y arreflexia<break/>-Patr&#x000f3;n desmielinizante, polirradiculoneuropat&#x000ed;a</td><td align="left">(-) LCR<break/>(+) Anticuerpos IgM, IgG</td><td align="left">-Ig</td><td align="left">Favorable</td></tr><tr><td align="left">Marta-Enguita J.<break/>Espa&#x000f1;a, 2020<xref rid="bib0265" ref-type="bibr"><sup>16</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino<break/>76 a&#x000f1;os</td><td align="left">-Tetraparesia, parestesia, arreflexia, debilidad extremidades, dolor irradiado, disfagia<break/>-Polirradiculoneuropat&#x000ed;a inflamatoria<break/>-Insuficiencia respiratoria<break/>-S&#x000ed;ndrome bulbar</td><td align="left">(+) PCR, hisopo<break/>nasofar&#x000ed;ngeo</td><td align="left">-Morfina, AINE, pirazolonas<break/>- Amoxicilina, azitromicina, &#x000e1;cido clavul&#x000e1;nico.</td><td align="left">&#x0253c;</td></tr><tr><td align="left">Oguz-Akarsu E.<break/>Turqu&#x000ed;a, 2020<xref rid="bib0270" ref-type="bibr"><sup>17</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino<break/>53 a&#x000f1;os</td><td align="left">-Disartria, debilidad y entumecimiento de extremidades<break/>- Arreflexia tendones profundos EEII<break/>-Patr&#x000f3;n desmielinizante</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo<break/><break/>(-) LCR</td><td align="left">-Transfusiones de plasma<break/>-Hidroxicloroquina, azitromicina</td><td align="left">Favorable</td></tr><tr><td align="left">Ottaviani D.<break/>Italia, 2020<xref rid="bib0285" ref-type="bibr"><sup>20</sup></xref></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino<break/>66 a&#x000f1;os</td><td align="left">-Par&#x000e1;lisis fl&#x000e1;cida, neuropat&#x000ed;a facial, paraplejia EEII, dificultad para caminar, debilidad distal EESS<break/>-Arreflexia difusa<break/>-Par&#x000e1;lisis facial<break/>-Patr&#x000f3;n desmielinizante<break/>-Falla multiorg&#x000e1;nica</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo<break/><break/>(-) LCR</td><td align="left">-Hidroxicloroquina, antivirales<break/>-Ig</td><td align="left">NR</td></tr><tr><td align="left">Padroni M.<break/>Italia, 2020<xref rid="bib0325" ref-type="bibr"><sup>27</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino<break/>70 a&#x000f1;os</td><td align="left">-Astenia, paresia, debilidad de extremidades, dificultad de la marcha, fiebre.<break/>-Arreflexia tendones profundos EEII.<break/>-Insuficiencia respiratoria</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo<break/></td><td align="left">-Ig<break/></td><td align="left">Favorable</td></tr><tr><td align="left">Rana S.<break/>EE.UU., 2020<xref rid="bib0330" ref-type="bibr"><sup>28</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino 54 a&#x000f1;os</td><td align="left">-Cuadraparesia y debilidad muscular progresiva<break/>-Arreflexia<break/>-Dificultad para orinar<break/>-Oftalmoparesia leve<break/>-Dificultad respiratoria&#x02192; Intubaci&#x000f3;n</td><td align="left">(+) PCR<break/>(-) LCR</td><td align="left">-Hidroxicloroquina<break/>-Azitromicina<break/>-Ig</td><td align="left">Favorable</td></tr><tr><td align="left">Reyes-Bueno J.A.<break/>Espa&#x000f1;a, 2020<xref rid="bib0245" ref-type="bibr"><sup>12</sup></xref></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino 51 a&#x000f1;os</td><td align="left">-Debilidad muscular extremidades inferiores<break/>-Paraparesia<break/>-Arreflexia global<break/>-Paresia facial inferior bilateral<break/>-Disfunci&#x000f3;n auton&#x000f3;mica (boca seca, diarrea, PA inestable)<break/>-Poliradiculoneuropat&#x000ed;a</td><td align="left">(-) PCR<break/>(+) IgG<break/>(test ELISA)</td><td align="left">-Ig<break/>-Gabapentina</td><td align="left">Favorable</td></tr><tr><td align="left">Sancho-Salda&#x000f1;a A.<break/>Espa&#x000f1;a, 2020<xref rid="bib0375" ref-type="bibr"><sup>29</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino56 a&#x000f1;os</td><td align="left">-Fiebre, tos seca, dificultad respiratoria<break/>-Debilidad muscular EEII<break/>-Tetraparesia<break/>-Arreflexia global<break/>-Par&#x000e1;lisis facial bilateral<break/>-Debilidad musculatura orofar&#x000ed;ngea</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo<break/>(-) LCR</td><td align="left">-Hidroxicloroquina<break/>-Azitromicina<break/>-Ig</td><td align="left">Favorable</td></tr><tr><td align="left">Scheidl E.<break/>Alemania, 2020<xref rid="bib0340" ref-type="bibr"><sup>30</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino 54 a&#x000f1;os</td><td align="left">-Paraparesia<break/>-Arreflexia<break/>-Anosmia transitoria<break/>-Disfagia</td><td align="left">(+) PCR,hisopo orofar&#x000ed;ngeo</td><td align="left">-Ig</td><td align="left">Favorable</td></tr><tr><td align="left">Sedaghat Z.<break/>Ir&#x000e1;n, 2020<xref rid="bib0345" ref-type="bibr"><sup>31</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino 65 a&#x000f1;os</td><td align="left">-Tos, fiebre, disnea<break/>-Cuadriplejia<break/>-Paresia facial bilateral<break/>-Arreflexia</td><td align="left">(+) PCR, hisopo orofar&#x000ed;ngeo<break/></td><td align="left">-Ig<break/>-Hidroxicloroquina, Azitromicina<break/>-Antirretrovirales</td><td align="left">Favorable</td></tr><tr><td align="left">Su XW.<break/>EE.UU., 2020<xref rid="bib0350" ref-type="bibr"><sup>32</sup></xref></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino 72 a&#x000f1;os</td><td align="left">-Diarrea, anorexia, escalofr&#x000ed;os<break/>- Debilidad muscular EESS y EEII<break/>-Distr&#x000e9;s respiratorio<break/></td><td align="left">(+) PCR x hisopo nasofar&#x000ed;ngeo<break/>(-) LCR</td><td align="left">-Ig<break/>-Antibi&#x000f3;ticos</td><td align="left">Desfavorable</td></tr><tr><td align="left">Toscano G.<break/>Italia, 2020<xref rid="bib0250" ref-type="bibr"><sup>13</sup></xref></td><td align="left">SC</td><td align="left">5</td><td align="left">NR</td><td align="left">-Fiebre, tos, anosmia (5 pacientes)<break/>-Tetraparesia arrefl&#x000e9;xica fl&#x000e1;cida (3 pacientes)<break/>-Paraparesia (1 paciente)<break/>-Paraplejia (1 paciente)<break/>-Debilidad facial (3 pacientes)<break/>-Diplejia facial (1 paciente)</td><td align="left">4 PCR +<break/>1 PCR - (positivo anticuerpos)<break/>hisopo nasofar&#x000ed;ngeo<break/>(-) LCR en 5 pacientes</td><td align="left">-Ig (5 pacientes)</td><td align="left">Lenta Favorable (3)<break/>Favorable (1)<break/>Desfavorable(1)<break/></td></tr><tr><td align="left">Velayos A.<break/>Espa&#x000f1;a, 2020<xref rid="bib0355" ref-type="bibr"><sup>33</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino 43 a&#x000f1;os</td><td align="left">-Diarrea, infecci&#x000f3;n respiratoria alta<break/>-Cuadriparesia, cuadriplejia<break/>-Arreflexia global<break/>-Paresia facial bilateral<break/>-Disfagia</td><td align="left">(+) PCR</td><td align="left">-Ig<break/>-Hidroxicloroquina<break/>-Antirretrovirales<break/>-Antibi&#x000f3;ticos<break/>-Corticoides</td><td align="left">Favorable</td></tr><tr><td align="left">Virani A.<break/>EE.UU., 2020<xref rid="bib0360" ref-type="bibr"><sup>34</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino 54 a&#x000f1;os</td><td align="left">-Fiebre, tos, diarrea<break/>-Debilidad y arreflexia extremidades inferiores y superiores<break/>-Dificultad respiratoria</td><td align="left">(+) PCR</td><td align="left">-Ig<break/>-Hidroxicloroquina</td><td align="left">Favorable</td></tr><tr><td align="left">Webb S.<break/>Inglaterra, 2020<xref rid="bib0365" ref-type="bibr"><sup>35</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Masculino 57 a&#x000f1;os</td><td align="left">-Tos, dolor de cabeza, mialgia<break/>-Debilidad muscular extremidades inferiores, paresia<break/>-Arreflexia global</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo<break/>(-) LCR</td><td align="left">-Ig</td><td align="left">Favorable</td></tr><tr><td align="left">Zhao H.<break/>China, 2020<xref rid="bib0370" ref-type="bibr"><sup>36</sup></xref><break/></td><td align="left">RC</td><td align="left">1</td><td align="left">Femenino 61 a&#x000f1;os</td><td align="left">-Fiebre, tos, dolor pecho, diarrea<break/>-Debilidad muscular EEII y arreflexia</td><td align="left">(+) PCR, hisopo nasofar&#x000ed;ngeo</td><td align="left">-Ig<break/>-Antirretrovirales<break/></td><td align="left">Favorable</td></tr></tbody></table><table-wrap-foot><fn><p>N: N&#x000fa;mero de pacientes, NR: No reportado, RC: Reporte de caso, SC: Serie de casos, EEII: Extremidad inferior, LCR: L&#x000ed;quido cefalorraqu&#x000ed;deo, PCR: Reacci&#x000f3;n en cadena de la polimerasa, Ig: Inmunoglobulinas, &#x0253c; Fallecido.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0020"><title>Discusi&#x000f3;n</title><p id="par0090">Es relevante mencionar que todos los centros de salud referenciados en los art&#x000ed;culos analizados han mostrado un aumento anormal de los pacientes ingresados con SGB, evidenciando una prevalencia etaria mucho mayor (media 60 a&#x000f1;os), que los casos de este s&#x000ed;ndrome pre-pandemia (media 40 a&#x000f1;os)<xref rid="bib0290" ref-type="bibr"><sup>21</sup></xref>. En este contexto es importante analizar a los dos pacientes fallecidos, ambos con edades mayores a los 70 a&#x000f1;os, al igual que el paciente con evoluci&#x000f3;n desfavorable. Dado que la variable edad corresponde a un factor de riesgo independiente a la mortalidad por COVID-19<xref rid="bib0295" ref-type="bibr"><sup>22</sup></xref> se necesitar&#x000e1;n m&#x000e1;s estudios de causalidad (ECA) para poder contar con resultados y conclusiones m&#x000e1;s certeras.</p><p id="par0095">Los s&#x000ed;ntomas previos al desarrollo de este s&#x000ed;ndrome, en la mayor&#x000ed;a de los casos, fueron ageusia e hiposmia, adem&#x000e1;s se evidenci&#x000f3; mayor gravedad respecto a los s&#x000ed;ntomas respiratorios del COVID-19, como la neumon&#x000ed;a<xref rid="bib0305" ref-type="bibr"><sup>23</sup></xref>. Es importante mencionar lo recalcado por Assini et al., respecto a las diferencias en la presentaci&#x000f3;n de este SGB versus los pre-pandemia, donde el deterioro de varios nervios craneales en asociaci&#x000f3;n con una neuropat&#x000ed;a perif&#x000e9;rica desmielinizante es una caracter&#x000ed;stica muy poco com&#x000fa;n que solo afecta al 5% de los casos reportados previamente, pero en este contexto asociado a COVID-19 se puede ver afectaci&#x000f3;n de los nervios craneales en el 47% de los pacientes incluidos en esta revisi&#x000f3;n y se presenta como una caracter&#x000ed;stica distintiva de los casos asociados a la pandemia<xref rid="bib0310" ref-type="bibr"><sup>24</sup></xref>.</p><p id="par0100">Respecto al tiempo de presentaci&#x000f3;n de las primeras manifestaciones neurol&#x000f3;gicas, tenemos que fluct&#x000fa;an entre los cinco y los 21 d&#x000ed;as posteriores a los s&#x000ed;ntomas del COVID-19.</p><p id="par0105">Llama la atenci&#x000f3;n que existe un porcentaje de pacientes (26,6%) a los que no se les realiz&#x000f3; testeo de LCR (l&#x000ed;quido cefalorraqu&#x000ed;deo), esto es importante ya que se ha evidenciado que esta evaluaci&#x000f3;n es de gran relevancia para realizar un correcto diagn&#x000f3;stico y un posterior tratamiento, especialmente en los pacientes que cursan un estado cr&#x000ed;tico<xref rid="bib0220" ref-type="bibr"><sup>7</sup></xref>.</p><p id="par0110">Los estudios analizados son reportes de caso, o series de casos, con bajo n&#x000fa;mero muestral, por lo que el an&#x000e1;lisis realizado los cataloga con alto riesgo de sesgo; sin embargo, a pesar de esta limitaci&#x000f3;n, es importante recalcar que se est&#x000e1; mostrando tendencia a asociaci&#x000f3;n entre ambas patolog&#x000ed;as descritas con esta nueva presentaci&#x000f3;n de s&#x000ed;ntomas.</p></sec><sec id="sec0025"><title>Conclusi&#x000f3;n</title><p id="par0115">Los estudios analizados demuestran una clara tendencia de asociaci&#x000f3;n entre ambas patolog&#x000ed;as, donde el virus SARS-CoV-2 ser&#x000ed;a el potencial gatillador del SGB. Son necesarios m&#x000e1;s estudios con dise&#x000f1;os m&#x000e1;s elevados en niveles de evidencia y muestras m&#x000e1;s representativas para poder hacer an&#x000e1;lisis concluyentes respecto a esta tem&#x000e1;tica; sin embargo, parece ser que, a diferencia de los cuadros anteriores, existe una mayor edad de presentaci&#x000f3;n en este s&#x000ed;ndrome, con afectaci&#x000f3;n de nervios craneales y manifestaciones cl&#x000ed;nicas m&#x000e1;s graves, aunque con tratamiento oportuno se muestran resultados favorables.</p><p id="par0120">Esperamos que esta revisi&#x000f3;n sea la antesala de futuros estudios que permitan a los profesionales de la salud y a la poblaci&#x000f3;n general estar m&#x000e1;s atentos respecto a la presencia de esta patolog&#x000ed;a en nuestros c&#x000ed;rculos cercanos.</p></sec><sec id="sec0030"><title>Conflicto de intereses</title><p id="par0125">Los autores declaran no tener ning&#x000fa;n conflicto de intereses.</p></sec><sec id="sec0035"><title>Financiaci&#x000f3;n</title><p id="par0130">Este trabajo no ha recibido ning&#x000fa;n tipo de financiaci&#x000f3;n.</p></sec></body><back><ref-list id="bibl0005"><title>Bibliograf&#x000ed;a</title><ref id="bib0190"><label>1</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention</surname></name></person-group><article-title>The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China</article-title><source>Zhonghua Liu Xing Bing Xue Za Zhi.</source><volume>41</volume><year>2020</year><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">32064853</pub-id></element-citation></ref><ref id="bib0195"><label>2</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Filatov</surname><given-names>A.</given-names></name><name><surname>Sharma</surname><given-names>P.</given-names></name><name><surname>Hindi</surname><given-names>F.</given-names></name><name><surname>Espinosa</surname><given-names>P.S.</given-names></name></person-group><article-title>Neurological complications of coronavirus disease (COVID- 19): Encephalopathy</article-title><source>Cureus.</source><volume>12</volume><year>2020</year><fpage>e7352</fpage><pub-id pub-id-type="pmid">32328364</pub-id></element-citation></ref><ref id="bib0200"><label>3</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Paliwal</surname><given-names>V.K.</given-names></name><name><surname>Garg</surname><given-names>R.K.</given-names></name></person-group><article-title>Is COVID-19-related Guillain-Barr&#x000e9; syndrome different?</article-title><source>Brain Behav Immun.</source><volume>87</volume><year>2020</year><fpage>177</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">32445789</pub-id></element-citation></ref><ref id="bib0205"><label>4</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.C.</given-names></name><name><surname>Bai</surname><given-names>W.Z.</given-names></name><name><surname>Hashikawa</surname><given-names>T.</given-names></name></person-group><article-title>The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients</article-title><source>J Med Virol.</source><volume>92</volume><year>2020</year><fpage>552</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">32104915</pub-id></element-citation></ref><ref id="bib0210"><label>5</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>Y.</given-names></name><name><surname>Rojas</surname><given-names>M.</given-names></name><name><surname>Pacheco</surname><given-names>Y.</given-names></name><name><surname>Acosta-Ampudia</surname><given-names>Y.</given-names></name><name><surname>Ram&#x000ed;rez-Santana</surname><given-names>C.</given-names></name><name><surname>Monsalve</surname><given-names>D.M.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome, transverse myelitis and infectious diseases</article-title><source>Cell Mol Immunol.</source><volume>15</volume><year>2018</year><fpage>547</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">29375121</pub-id></element-citation></ref><ref id="bib0215"><label>6</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I.</given-names></name><name><surname>Timens</surname><given-names>W.</given-names></name><name><surname>Bulthuis</surname><given-names>M.L.C.</given-names></name><name><surname>Lely</surname><given-names>A.T.</given-names></name><name><surname>Navis</surname><given-names>G.J.</given-names></name><name><surname>Van Goor</surname><given-names>H.</given-names></name></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J Pathol.</source><volume>203</volume><year>2004</year><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="bib0220"><label>7</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Duan</surname><given-names>J.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name></person-group><article-title>Nervous system involvement after infection with COVID-19 and other coronaviruses</article-title><source>Brain Behav Immun.</source><volume>87</volume><year>2020</year><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">32240762</pub-id></element-citation></ref><ref id="bib0225"><label>8</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Letko</surname><given-names>M.</given-names></name><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Munster</surname><given-names>V.</given-names></name></person-group><article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title><source>Nat Microbiol.</source><volume>5</volume><year>2020</year><fpage>562</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">32094589</pub-id></element-citation></ref><ref id="bib0230"><label>9</label><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>K.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Aihara</surname><given-names>H.</given-names></name></person-group><article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title><source>Nature.</source><volume>581</volume><year>2020</year><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">32225175</pub-id></element-citation></ref><ref id="bib0235"><label>10</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Needham</surname><given-names>E.J.</given-names></name><name><surname>Chou</surname><given-names>S.H.Y.</given-names></name><name><surname>Coles</surname><given-names>A.J.</given-names></name><name><surname>Menon</surname><given-names>D.K.</given-names></name></person-group><article-title>Neurological Implications of COVID-19 Infections</article-title><source>Neurocrit Care.</source><volume>32</volume><year>2020</year><fpage>667</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">32346843</pub-id></element-citation></ref><ref id="bib0240"><label>11</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>E.</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>M.</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>P.</given-names></name><name><surname>Carrillo</surname><given-names>A.</given-names></name><name><surname>Sancho</surname><given-names>I.</given-names></name><name><surname>Sanjuan-Villarreal</surname><given-names>T.A.</given-names></name></person-group><article-title>S&#x000ed;ndrome de Guillain-Barr&#x000e9; asociado a infecci&#x000f3;n por COVID-19</article-title><source>Med Intensiva.</source><year>2020</year><comment>DOI: 10.1016/j.medin.2020.04.015</comment></element-citation></ref><ref id="bib0245"><label>12</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Reyes-Bueno</surname><given-names>J.A.</given-names></name><name><surname>Garc&#x000ed;a-Trujillo</surname><given-names>L.</given-names></name><name><surname>Urbaneja</surname><given-names>P.</given-names></name><name><surname>Ciano-Petersen</surname><given-names>N.L.</given-names></name><name><surname>Postigo-Pozo</surname><given-names>M.J.</given-names></name><name><surname>Mart&#x000ed;nez-Tom&#x000e1;s</surname><given-names>C.</given-names></name></person-group><article-title>Miller-Fisher syndrome after SARS-CoV-2 infection</article-title><source>Eur J Neurol.</source><year>2020</year><comment>doi:10.1111/ene.14383</comment></element-citation></ref><ref id="bib0250"><label>13</label><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name><surname>Toscano</surname><given-names>G.</given-names></name><name><surname>Palmerini</surname><given-names>F.</given-names></name><name><surname>Ravaglia</surname><given-names>S.</given-names></name><name><surname>Ruiz</surname><given-names>L.</given-names></name><name><surname>Invernizzi</surname><given-names>P.</given-names></name><name><surname>Cuzzoni</surname><given-names>M.G.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; Syndrome Associated with SARS-CoV-2</article-title><source>N Engl J Med.</source><volume>382</volume><year>2020</year><fpage>2574</fpage><lpage>2576</lpage><pub-id pub-id-type="pmid">32302082</pub-id></element-citation></ref><ref id="bib0255"><label>14</label><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name><surname>Kilinc</surname><given-names>D.</given-names></name><name><surname>Van de Pasch</surname><given-names>S.</given-names></name><name><surname>Doets</surname><given-names>A.Y.</given-names></name><name><surname>Jacobs</surname><given-names>B.C.</given-names></name><name><surname>Van Vliet</surname><given-names>J.</given-names></name><name><surname>Garssen</surname><given-names>M.P.J.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome after SARS-CoV-2 infection</article-title><source>Eur J Neurol.</source><year>2020</year><comment>https://doi.org/10.1111/ene.14398</comment></element-citation></ref><ref id="bib0260"><label>15</label><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name><surname>Juliao Caama&#x000f1;o</surname><given-names>D.S.</given-names></name><name><surname>Alonso Beato</surname><given-names>R.</given-names></name></person-group><article-title>Facial diplegia, a possible atypical variant of Guillain-Barr&#x000e9; Syndrome as a rare neurological complication of SARS-CoV-2</article-title><source>J Clin Neurosci.</source><volume>77</volume><year>2020</year><fpage>230</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">32410788</pub-id></element-citation></ref><ref id="bib0265"><label>16</label><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Marta-Enguita</surname><given-names>J.</given-names></name><name><surname>Rubio-Baines</surname><given-names>I.</given-names></name><name><surname>Gast&#x000f3;n-Zubimendi</surname><given-names>I.</given-names></name></person-group><article-title>S&#x000ed;ndrome de Guillain-Barr&#x000e9; fatal tras infecci&#x000f3;n por virus SARS-CoV2</article-title><source>Neurolog&#x000ed;a.</source><volume>35</volume><year>2020</year><fpage>265</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">32364124</pub-id></element-citation></ref><ref id="bib0270"><label>17</label><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Oguz-Akarsu</surname><given-names>E.</given-names></name><name><surname>Ozpar</surname><given-names>R.</given-names></name><name><surname>Mirzayev</surname><given-names>H.</given-names></name><name><surname>Acet-Ozturk</surname><given-names>N.A.</given-names></name><name><surname>Hakyemez</surname><given-names>B.</given-names></name><name><surname>Ediger</surname><given-names>D.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; Syndrome in a Patient with Minimal Symptoms of COVID-19 Infection</article-title><source>Muscle Nerve.</source><year>2020</year><comment>doi:10.1002/mus.26992</comment></element-citation></ref><ref id="bib0275"><label>18</label><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>P.</given-names></name><name><surname>Beretta</surname><given-names>S.</given-names></name><name><surname>Piatti</surname><given-names>M.</given-names></name><name><surname>Karantzoulis</surname><given-names>A.</given-names></name><name><surname>Piatti</surname><given-names>M.L.</given-names></name><name><surname>Santoro</surname><given-names>P.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome related to COVID-19 infection</article-title><source>Neurol Neuroimmunol Neuroinflamm.</source><volume>7</volume><year>2020</year><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="bib0280"><label>19</label><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name><surname>Camdessanche</surname><given-names>J.P.</given-names></name><name><surname>Morel</surname><given-names>J.</given-names></name><name><surname>Pozzetto</surname><given-names>B.</given-names></name><name><surname>Paul</surname><given-names>S.</given-names></name><name><surname>Tholance</surname><given-names>Y.</given-names></name><name><surname>Botelho- Nevers</surname><given-names>E.</given-names></name></person-group><article-title>COVID-19 may induce Guillain-Barr&#x000e9; syndrome</article-title><source>Rev Neurol (Paris).</source><volume>176</volume><year>2020</year><fpage>516</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">32334841</pub-id></element-citation></ref><ref id="bib0285"><label>20</label><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Ottaviani</surname><given-names>D.</given-names></name><name><surname>Boso</surname><given-names>F.</given-names></name><name><surname>Tranquillini</surname><given-names>E.</given-names></name><name><surname>Gapeni</surname><given-names>I.</given-names></name><name><surname>Pedrotti</surname><given-names>G.</given-names></name><name><surname>Cozzio</surname><given-names>S.</given-names></name></person-group><article-title>Early Guillain-Barr&#x000e9; syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital</article-title><source>Neurol Sci.</source><volume>41</volume><year>2020</year><fpage>1351</fpage><lpage>1354</lpage><pub-id pub-id-type="pmid">32399950</pub-id></element-citation></ref><ref id="bib0290"><label>21</label><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name><surname>Baig</surname><given-names>A.M.</given-names></name></person-group><article-title>Updates on What ACS Reported: Emerging Evidences of COVID-19 with Nervous System Involvement</article-title><source>ACS Chem Neurosci.</source><volume>11</volume><year>2020</year><fpage>1204</fpage><lpage>1205</lpage><pub-id pub-id-type="pmid">32343122</pub-id></element-citation></ref><ref id="bib0295"><label>22</label><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Tu</surname><given-names>W.J.</given-names></name><name><surname>Cheng</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.K.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name></person-group><article-title>Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China</article-title><source>Clin Infect Dis.</source><year>2020</year><comment>DOI: 10.1093/cid/ciaa243</comment></element-citation></ref><ref id="bib0305"><label>23</label><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name><surname>Arnaud</surname><given-names>S.</given-names></name><name><surname>Budowski</surname><given-names>C.</given-names></name><name><surname>Ng Wing Tin</surname><given-names>S.</given-names></name><name><surname>Degos</surname><given-names>B.</given-names></name></person-group><article-title>Post SARS-CoV-2 Guillain-Barr&#x000e9; syndrome</article-title><source>Clin Neurophysiol.</source><volume>131</volume><year>2020</year><fpage>1652</fpage><lpage>1654</lpage><pub-id pub-id-type="pmid">32422529</pub-id></element-citation></ref><ref id="bib0310"><label>24</label><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name><surname>Assini</surname><given-names>A.</given-names></name><name><surname>Benedetti</surname><given-names>L.</given-names></name><name><surname>Di Maio</surname><given-names>S.</given-names></name><name><surname>Schirinzi</surname><given-names>E.</given-names></name><name><surname>Del Sette</surname><given-names>M.</given-names></name></person-group><article-title>New clinical manifestation of COVID-19 related Guillain-Barr&#x000e8; syndrome highly responsive to intravenous immunoglobulins: two Italian cases</article-title><source>Neurol Sci.</source><volume>41</volume><year>2020</year><fpage>1657</fpage><lpage>11658</lpage><pub-id pub-id-type="pmid">32468450</pub-id></element-citation></ref><ref id="bib0315"><label>25</label><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name><surname>Bigaut</surname><given-names>K.</given-names></name><name><surname>Mallaret</surname><given-names>M.</given-names></name><name><surname>Baloglu</surname><given-names>S.</given-names></name><name><surname>Nemoz</surname><given-names>B.</given-names></name><name><surname>Morand</surname><given-names>P.</given-names></name><name><surname>Baicry</surname><given-names>F.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome related to SARS-CoV-2 infection</article-title><source>Neurol Neuroimmunol Neuroinflamm.</source><volume>7</volume><year>2020</year><fpage>e785</fpage><comment>DOI: 10.1212/NXI.0000000000000785</comment><pub-id pub-id-type="pmid">32461235</pub-id></element-citation></ref><ref id="bib0320"><label>26</label><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name><surname>El Otmani</surname><given-names>H.</given-names></name><name><surname>El Moutawakil</surname><given-names>B.</given-names></name><name><surname>Rafai</surname><given-names>M.A.</given-names></name><name><surname>El Benna</surname><given-names>N.</given-names></name><name><surname>El Kettani</surname><given-names>C.</given-names></name><name><surname>Soussi</surname><given-names>M.</given-names></name></person-group><article-title>Covid-19 and Guillain-Barr&#x000e9; syndrome: More than a coincidence!</article-title><source>Rev Neurol (Paris).</source><volume>176</volume><year>2020</year><fpage>518</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">32359804</pub-id></element-citation></ref><ref id="bib0325"><label>27</label><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name><surname>Padroni</surname><given-names>M.</given-names></name><name><surname>Mastrangelo</surname><given-names>V.</given-names></name><name><surname>Asioli</surname><given-names>G.M.</given-names></name><name><surname>Pavolucci</surname><given-names>L.</given-names></name><name><surname>Abu-Rumeileh</surname><given-names>S.</given-names></name><name><surname>Piscaglia</surname><given-names>M.G.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome following COVID-19: new infection, old complication?</article-title><source>J Neurol.</source><volume>267</volume><year>2020</year><fpage>1877</fpage><lpage>1879</lpage><pub-id pub-id-type="pmid">32333166</pub-id></element-citation></ref><ref id="bib0330"><label>28</label><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name><surname>Rana</surname><given-names>S.</given-names></name><name><surname>Lima</surname><given-names>A.A.</given-names></name><name><surname>Chandra</surname><given-names>R.</given-names></name><name><surname>Valeriano</surname><given-names>J.</given-names></name><name><surname>Desai</surname><given-names>T.</given-names></name><name><surname>Freiberg</surname><given-names>W.</given-names></name></person-group><article-title>Novel Coronavirus (COVID-19)-Associated Guillain-Barr&#x000e9; Syndrome: Case Report</article-title><source>J Clin Neuromuscul Dis.</source><volume>21</volume><year>2020</year><fpage>240</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">32453100</pub-id></element-citation></ref><ref id="bib0375"><label>29</label><element-citation publication-type="journal" id="sbref0375"><person-group person-group-type="author"><name><surname>Sancho-Salda&#x000f1;a</surname><given-names>A.</given-names></name><name><surname>Lambea-Gil</surname><given-names>&#x000c1;.</given-names></name><name><surname>Capablo Liesa</surname><given-names>J.L.</given-names></name><name><surname>Barrena Caballo</surname><given-names>M.R.</given-names></name><name><surname>Garay</surname><given-names>M.H.</given-names></name><name><surname>Celada</surname><given-names>D.R.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection</article-title><source>Clin Med (Lond).</source><volume>20</volume><year>2020</year><fpage>e93</fpage><lpage>e94</lpage><pub-id pub-id-type="pmid">32518103</pub-id></element-citation></ref><ref id="bib0340"><label>30</label><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name><surname>Scheidl</surname><given-names>E.</given-names></name><name><surname>Diez Canseco</surname><given-names>D.</given-names></name><name><surname>Hadji-Naumov</surname><given-names>A.</given-names></name><name><surname>Bereznai</surname><given-names>B.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature</article-title><source>J Peripher Nerv Syst.</source><volume>25</volume><year>2020</year><fpage>204</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">32388880</pub-id></element-citation></ref><ref id="bib0345"><label>31</label><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name><surname>Sedaghat</surname><given-names>Z.</given-names></name><name><surname>Karimi</surname><given-names>N.</given-names></name></person-group><article-title>Guillain Barre syndrome associated with COVID-19 infection: A case report</article-title><source>J Clin Neurosci.</source><volume>76</volume><year>2020</year><fpage>233</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">32312628</pub-id></element-citation></ref><ref id="bib0350"><label>32</label><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X.W.</given-names></name><name><surname>Palka</surname><given-names>S.V.</given-names></name><name><surname>Rao</surname><given-names>R.R.</given-names></name><name><surname>Chen</surname><given-names>F.S.</given-names></name><name><surname>Brackney</surname><given-names>C.R.</given-names></name><name><surname>Cambi</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2-associated Guillain-Barr&#x000e9; syndrome with dysautonomia</article-title><source>Muscle Nerve.</source><volume>62</volume><year>2020</year><fpage>E48</fpage><lpage>E49</lpage><comment>doi: 10.1002/mus.26988</comment><pub-id pub-id-type="pmid">32445201</pub-id></element-citation></ref><ref id="bib0355"><label>33</label><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name><surname>Velayos Gal&#x000e1;n</surname><given-names>A.</given-names></name><name><surname>Del Saz Saucedo</surname><given-names>P.</given-names></name><name><surname>Peinado Postigo</surname><given-names>F.</given-names></name><name><surname>Botia Paniagua</surname><given-names>E.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome associated with SARS-CoV-2 infection</article-title><source>Neurologia.</source><volume>35</volume><year>2020</year><fpage>268</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32364123</pub-id></element-citation></ref><ref id="bib0360"><label>34</label><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name><surname>Virani</surname><given-names>A.</given-names></name><name><surname>Rabold</surname><given-names>E.</given-names></name><name><surname>Hanson</surname><given-names>T.</given-names></name><name><surname>Haag</surname><given-names>A.</given-names></name><name><surname>Elrufay</surname><given-names>R.</given-names></name><name><surname>Cheema</surname><given-names>T.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; Syndrome associated with SARS-CoV-2 infection</article-title><source>IDCases.</source><volume>20</volume><year>2020</year><fpage>e00771</fpage><comment>doi: 10.1016/j.idcr.2020.e00771.</comment><pub-id pub-id-type="pmid">32313807</pub-id></element-citation></ref><ref id="bib0365"><label>35</label><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>S.</given-names></name><name><surname>Wallace</surname><given-names>V.C.</given-names></name><name><surname>Martin-Lopez</surname><given-names>D.</given-names></name><name><surname>Yogarajah</surname><given-names>M.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome following COVID-19: a newly emerging post-infectious complication</article-title><source>BMJ Case Rep.</source><volume>13</volume><year>2020</year><fpage>e236182</fpage><comment>doi: 10.1136/bcr-2020-236182</comment></element-citation></ref><ref id="bib0370"><label>36</label><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>D.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name></person-group><article-title>Guillain-Barr&#x000e9; syndrome associated with SARS-CoV-2 infection: causality or coincidence?</article-title><source>Lancet Neurol.</source><volume>19</volume><year>2020</year><fpage>383</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">32246917</pub-id></element-citation></ref></ref-list></back></article>